Phaseline

Targets › CCK2R

CCK2R: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Apr 2027.

Open in Phaseline: the race on CCK2R, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University Hospital, Basel, Switzerland177Lu-PP-F11N
Cholecystokinin-2 receptor ligand (gastrin analogue)
CCK2RPhase 1Thyroid Cancer, MedullaryApr 2027

Conditions

Thyroid Cancer, Medullary (1)

Modalities

small molecule (1)

Companies

University Hospital, Basel, Switzerland (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.